Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Randomized Clinical Study to Evaluate Pharmacokinetic (PK) Profiles, Safety, and Tolerability of Abexinostat Monotherapy in Patients With Non-Hodgkin's Lymphoma Who Have Failed Standard of Care

NCT04024696 is registered in ClinicalTrials.gov with Xynomic Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04024696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04024696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Randomized Clinical Study to Evaluate Pharmacokinetic (PK) Profiles, Safety, and Tolerability of Abexinostat Monotherapy in Patients With Non-Hodgkin's Lymphoma Who Have Failed Standard of Care
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 8, 2020
Completion date
November 30, 2025
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma